171 related articles for article (PubMed ID: 35479835)
1. Targeting CXCL12/CXCR4 Signaling with AMD3100 Might Selectively Suppress CXCR4+ T-Cell Chemotaxis Leading to the Alleviation of Chronic Prostatitis.
Zhang M; Liu Y; Chen J; Chen L; Zhang L; Chen X; Hao Z; Liang C
J Inflamm Res; 2022; 15():2551-2566. PubMed ID: 35479835
[TBL] [Abstract][Full Text] [Related]
2. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
3. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
4. Study on the mechanism of CXCL12/CXCR4-axis-mediated upregulation of IL-8 and IL-6 on the biological function of acute T lymphocyte leukaemia cells.
Zhou L; Zhao H; Zhang C; Chen Z; Li D; Qian G
Cytotechnology; 2024 Feb; 76(1):97-111. PubMed ID: 38304623
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
[TBL] [Abstract][Full Text] [Related]
6. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
Yoshida D; Koketshu K; Nomura R; Teramoto A
J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
[TBL] [Abstract][Full Text] [Related]
7. CXCL12/CXCR4 signaling mediated ERK1/2 activation in spinal cord contributes to the pathogenesis of postsurgical pain in rats.
Xing F; Kong C; Bai L; Qian J; Yuan J; Li Z; Zhang W; Xu JT
Mol Pain; 2017; 13():1744806917718753. PubMed ID: 28633557
[TBL] [Abstract][Full Text] [Related]
8. NF-κB2 Controls the Migratory Activity of Memory T Cells by Regulating Expression of CXCR4 in a Mouse Model of Sjögren's Syndrome.
Kurosawa M; Arakaki R; Yamada A; Tsunematsu T; Kudo Y; Sprent J; Ishimaru N
Arthritis Rheumatol; 2017 Nov; 69(11):2193-2202. PubMed ID: 28804991
[TBL] [Abstract][Full Text] [Related]
9. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
10. CXCL12/CXCR4 signaling contributes to neuropathic pain via central sensitization mechanisms in a rat spinal nerve ligation model.
Liu ZY; Song ZW; Guo SW; He JS; Wang SY; Zhu JG; Yang HL; Liu JB
CNS Neurosci Ther; 2019 Sep; 25(9):922-936. PubMed ID: 30955244
[TBL] [Abstract][Full Text] [Related]
11. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis.
De Klerck B; Geboes L; Hatse S; Kelchtermans H; Meyvis Y; Vermeire K; Bridger G; Billiau A; Schols D; Matthys P
Arthritis Res Ther; 2005; 7(6):R1208-20. PubMed ID: 16277673
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury.
Saiman Y; Jiao J; Fiel MI; Friedman SL; Aloman C; Bansal MB
Hepatol Res; 2015 Jul; 45(7):794-803. PubMed ID: 25163538
[TBL] [Abstract][Full Text] [Related]
13. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological blockage of the CXCR4-CXCL12 axis in endometriosis leads to contrasting effects in proliferation, migration, and invasion.
Ruiz A; Ruiz L; Colón-Caraballo M; Torres-Collazo BJ; Monteiro JB; Bayona M; Fazleabas AT; Flores I
Biol Reprod; 2018 Jan; 98(1):4-14. PubMed ID: 29161347
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.
Scupoli MT; Donadelli M; Cioffi F; Rossi M; Perbellini O; Malpeli G; Corbioli S; Vinante F; Krampera M; Palmieri M; Scarpa A; Ariola C; Foà R; Pizzolo G
Haematologica; 2008 Apr; 93(4):524-32. PubMed ID: 18322253
[TBL] [Abstract][Full Text] [Related]
17. Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer.
Liu X; Xiao Q; Bai X; Yu Z; Sun M; Zhao H; Mi X; Wang E; Yao W; Jin F; Zhao L; Ren J; Wei M
Oncol Rep; 2014 Dec; 32(6):2760-8. PubMed ID: 25310198
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between astrocytic CXCL12 and microglial CXCR4 contributes to the development of neuropathic pain.
Luo X; Tai WL; Sun L; Pan Z; Xia Z; Chung SK; Cheung CW
Mol Pain; 2016; 12():. PubMed ID: 27030717
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model.
Cho KS; Yoon SJ; Lee JY; Cho NH; Choi YD; Song YS; Hong SJ
Oncol Lett; 2013 Oct; 6(4):933-938. PubMed ID: 24137439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
